Real-World study tracks Brigatinib's performance in chinese lung cancer patients
NCT ID NCT05721950
First seen Feb 28, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes their medical records without giving any new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Department of Oncology, Shanghai pulmonary hospital
Shanghai, Shanghai Municipality, 200433, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brigatinib (Alunbrig)
What this could lead to
If successful, this study could confirm that brigatinib is effective and safe for Chinese patients with ALK-positive lung cancer in everyday clinical practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient differences and real-world factors. It does not test a new treatment, only gathers data on existing use.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.